Markets
LAB

Why Fluidigm Stock Surged Today

What happened 

Shares of Fluidigm (NASDAQ: FLDM) soared on Wednesday after the biotechnology tools provider said its new saliva-based test for SARS‑CoV‑2 -- the virus that causes COVID-19 -- received emergency use authorization from the U.S. Food and Drug Administration (FDA). As of 1:13 a.m. EDT, Fluidigm's stock was up more than 35%.

So what

Since it uses saliva samples, Fluidigm's test is easier to perform for medical professionals -- and far more comfortable for patients -- than tests that require nasal swabs. Yet Fluidigm said its test, called the Advanta Dx SARS-CoV-2 RT-PCR Assay, generated results that were in 100% agreement with the results from paired nasal-swab samples tested with other FDA-authorized assays.

A person wearing gloves is placing a swab in a test tube.

Investors are excited about the market potential of Fluidigm's new coronavirus test. stock Image source: Getty Images.

Additionally, Fluidigm said its test has production advantages that will ease the strain on the healthcare industry's supply chains. Its Biomark HD platform can produce as many as 6,000 test results per day on a single system.

"We have seen extraordinarily strong customer interest in our high-throughput saliva-based test, including many new purchases of Biomark HD systems to enable its adoption," Fluidigm CEO Chris Linthwaite said in a press release. "We have a high degree of confidence that this new test will not only enhance testing capacity but will also significantly improve speed to results and scale."

Now what

Fluidigm's assay is not the only saliva-based coronavirus test that's been authorized for emergency use by the FDA. A diagnostic test created by the Yale School of Public Health and funded in part by the NBA was granted an emergency use authorization earlier this month. Moreover, Yale's test is expected to cost only about $10 per sample. 

Still, with COVID-19 case counts continuing to rise in the U.S. and around the world, there will likely be room for multiple diagnostic options. For its part, Fluidigm expects to see strong and sustained demand for its assay. "In the United States, Emergency Use Authorization for our test coincides with the total number of COVID-19 cases exceeding 5.7 million, underscoring the need for scalable and easy-to-administer testing," Linthwaite said.

10 stocks we like better than Fluidigm
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Fluidigm wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of August 1, 2020

 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

LAB

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More